Hypertension Interventions Have Limited Success in Rural Black Populations
Hypertension remains a significant problem in areas of the rural South.
In This Issue: Drug Topics March 2024
See what's trending in pharmacy with a preview the Drug Topics March issue.
Small Doses: March 11 to March 15
Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.
Telehealth-Based OUD Treatment May Lead to Better Health, Obstetric Outcomes Among Pregnant Patients
Telehealth mitigates barriers like stigma, fear, and legal concerns associated with receiving opioid use disorder (OUD) care by offering a convenient and discreet treatment option.
FDA Approves Lisocabtagene Maraleucel For Treatment of Relapsed or Refractory CLL, SLL
The approval was based on data from the phase 1/2 TRANSCEND CLL 004 study, in which the CAR T cell therapy demonstrated statistically significant complete response rates.
FDA Approves Resmetirom as First-Ever Treatment For MASH
The approval, awarded to Madrigal Pharmaceuticals, was based on phase 3 data demonstrating that resmetirom achieved broad treatment effects in patients with MASH with liver fibrosis.
Interventional Techniques Can Help Manage Pain in Patients With Cancer
With growing concerns around opioid use disorder, interventional pain management for patients with cancer can provide effective relief without the side effects associated with medication.
California Wildfires in the 2010s Exacerbated Psychotropic Medication Prescriptions
Researchers studied the effect of wildfires on mental health in California from 2011 to 2018.
How Daylight Saving Time Increases Overall Health Risks
Recent studies on daylight saving time’s association with increased health risks have heightened the debate on whether to observe the biannual event or switch to one universal time.
CDC Says US Will Transition to Trivalent Vaccines Next Flu Season
Since changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.
Psilocybin Analog for Treatment of Depression Receives FDA Breakthrough Therapy Designation
Cybin’s proprietary deuterated psilocybin analog, CYB003, provided robust and sustained improvements in depression symptoms in a phase 2 study.
Pediatric Medical Spending on Mental Health Increased by 31% in 4-Year Period
Medical spending on pediatric mental health conditions accounted for 46.6% of all pediatric medical spending in 2021.
Patients With T2D Often Lack Knowledge That Could Help Manage Disease
The implementation of targeted educational interventions might improve knowledge gaps, which pose great risk to patients, in type 2 diabetes (T2D) management.
Fish, Omega-3 Fatty Acid Intake Below Recommended Levels Among Pregnant Women
N-3 polyunsaturated fatty acids (PUFAs) are essential nutrients, especially during pregnancy as they support neurodevelopment in offspring and improve pregnancy outcomes.
Assessing the Current and Future Landscape of Pharmacy
A panel discussion at the Outcomes 2024 SYNC National Conference touched upon many important themes in community pharmacy, including the evolving role of pharmacists, emerging tech, and key challenges going forward.
Complementary Health Approaches for Pain Management Increasing in Popularity
Complementary health approaches, like yoga or acupuncture, can be particularly appealing to patients seeking natural and non-invasive approaches to improve their health.
Small Doses: March 4 to March 8
Rx Roundup: Quiz of the Week — March 8, 2024
Test your pharmacy news knowledge with our weekly quiz.
FDA Approves Nivolumab Plus Chemotherapy for Unresectable or Metastatic Urothelial Carcinoma
A clinical trial showed that nivolumab plus chemotherapy significantly improved overall survival and progression-free survival compared with a chemotherapy combination alone.
FDA Grants Breakthrough Therapy Designation to LSD-Based Treatment for Generalized Anxiety Disorder
Mind Medicine’s lysergide d-tartrate (MM120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in a phase 2b study.
Independent Pharmacies Continue to Face Financial Hardships as the Clock Ticks on PBM Reform
As pharmacy benefit managers gain leverage to continue driving up drug prices, local pharmacies struggle to keep up and Congress has been called to act—but it might be too late.
Tocilizumab-aazg Is First IV, Subcutaneous Tocilizumab Biosimilar With FDA Approval
The biosimilar represents a comprehensive, accessible, and high-quality treatment option for patients in the US treated with tocilizumab.
HHS Says It’s Working to Help Those Impacted by Change Healthcare Cyberattack
The statement says the agency is talking with CMS to initiate new flexibilities, but multiple advocacy groups have said it’s not nearly enough.
Ozempic Lowers Risk of Kidney Disease Progression, Cardiovascular Events by 24%
Positive results from the FLOW trial demonstrate the potential for Ozempic to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.
Breaking: Benzene Found in Acne Products From Major Brands, Prompts FDA Recall Petition
Following investigation by the independent testing laboratory, Valisure found acne products that contain up to 12 times the allowed of benzene.
Breaking: FDA Clears Dexcom Stelo, First OTC Continuous Glucose Monitor
Dexcom's Stelo will be available in summer 2024.
FDA Approves Interchangeable Denosumab Biosimilar
The agency approved denosumab-bddz under two brand names: Wyost and Jubbonti.
Government, Industry Leaders Address the Growing Issue of PBM Practices
Health care professionals, industry leaders, and politicians gathered for a virtual roundtable to discuss the state of the PBM industry.
FDA Approves Eye Drops to Treat Inflammation, Pain After Ocular Surgery
Clobetasol propionate ophthalmic suspension 0.05% is the first ophthalmic clobetasol propionate product approved by the FDA and is the first new ophthalmic steroid on the market in over 15 years.
Dupilumab Safe, Effective for Atopic Dermatitis in Real-Life Settings
In 2017, dupilumab became the first treatment approved in Canada for moderate to severe AD, as multiple clinical trials demonstrated its effectiveness and safety.
